Exopharm Share Price and Company Fundamentals



Price
$0.63
Change
-0.005 (-0.787%)
52 week
0.16 - 0.96

Last traded: Today at 4:39 AM

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Naïve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

9.13

Dividend yield

Beta

0.98

Market cap

$87.83M

Enterprise value

$92.57M

Company profile

Primary activitiesBiopharmaceutical research with a primary focus on developing and commercialising exosomes as therapeutic agents.
Industry / SectorBiotechnology / Healthcare
Full time employees41
Websitehttp://www.exopharm.com
Mailing address31 Queen Street Level 17 Melbourne VIC 3000 Australia
Phone / Fax61 3 9111 0026 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Exopharm does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Exopharm.

NameTitleAgeTotal Pay
Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.Company Founder, Technology Co-Founder, MD & Director255k
Dr. Gregor Lichtfuss M.Sc.Chief Operating Officer230.36k
Dr. Christopher Baldwin Ph.D.Chief Commercial Officer320.93k
Ms. Elizabeth McGregor B.A., M.B.A.Company Sec. & Non-Exec. Director

Profitability and management effectiveness

Profit margin

-273.96%

Operating margin

-274.85%

Return on assets

-49.40%

Return on equity

-91.89%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Exopharm is 87.83M and its enterprise value is 92.57M. The enterprise value to revenue ratio of EX1 is 34.09.

The EX1's stocks Beta value is 0.98 making it 2% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Exopharm (EX1)

Exopharm (ASX:EX1) Frequently Asked Questions

1. What is Exopharm's Stock Symbol?

Exopharm trades on ASX under the ticker symbol "EX1".

2. What is Exopharm's stock price today?

One share of EX1 stock can currently be purchased for approximately $0.63.

3. How can I contact Exopharm?

Exopharm's mailing address is 31 Queen Street Level 17 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9111 0026.

4. What is Exopharm's official website?

The official website of Exopharm is http://www.exopharm.com.

5. Which share registry manages Exopharm's stock?

Exopharm's stock is managed by AUTOMIC REGISTRY SERVICES.